Detalhe da pesquisa
1.
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.
Clin Infect Dis
; 78(4): 1056-1064, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38051664
2.
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024.
MMWR Morb Mortal Wkly Rep
; 73(8): 180-188, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38421945
3.
Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants.
J Infect Dis
; 228(3): 235-244, 2023 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883903
4.
Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.
Clin Infect Dis
; 76(6): 1030-1037, 2023 03 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327388
5.
Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States.
Clin Infect Dis
; 76(3): e460-e468, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580849
6.
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Clin Infect Dis
; 77(4): 547-557, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37255285
7.
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.
MMWR Morb Mortal Wkly Rep
; 72(17): 463-468, 2023 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104244
8.
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023.
MMWR Morb Mortal Wkly Rep
; 72(40): 1083-1088, 2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37796753
9.
mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients.
J Infect Dis
; 226(5): 797-807, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385875
10.
Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021.
J Infect Dis
; 225(10): 1694-1700, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932114
11.
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States.
Clin Infect Dis
; 75(Suppl 2): S159-S166, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35675695
12.
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States.
Clin Infect Dis
; 74(9): 1515-1524, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34358310
13.
Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(12): 459-465, 2022 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35324878
14.
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
MMWR Morb Mortal Wkly Rep
; 71(42): 1327-1334, 2022 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264830
15.
Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
MMWR Morb Mortal Wkly Rep
; 71(4): 118-124, 2022 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35085218
16.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
MMWR Morb Mortal Wkly Rep
; 71(5152): 1625-1630, 2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580424
17.
Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution.
Am J Emerg Med
; 54: 97-101, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151018
18.
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
MMWR Morb Mortal Wkly Rep
; 70(38): 1337-1343, 2021 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34555004
19.
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021.
MMWR Morb Mortal Wkly Rep
; 70(34): 1156-1162, 2021 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34437524
20.
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
JAMA
; 326(20): 2043-2054, 2021 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34734975